Precigen, Inc. (PGEN) Stock Price & How to Invest
Short answer
Precigen (PGEN) is a small-cap biopharmaceutical company that turned into a commercial-stage story in 2025 when the FDA approved Papzimeos, its gene-therapy immunotherapy for recurrent respiratory papillomatosis (RRP). You are buying a single-product launch ramp with a large addressable rare-disease niche, priced by the market well ahead of trailing revenue.
PGEN stock price
As of 2026-07-08, Precigen, Inc. (PGEN) last closed at $5.56, up 192.6% over the past year. Over the past 52 weeks it has traded between $1.52 and $5.92.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Precigen, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Precigen, Inc. (PGEN) do?
Precigen, Inc. is a Maryland-based biopharmaceutical company that develops precision medicines using its proprietary gene- and cell-therapy platforms, most notably the AdenoVerse gorilla-adenovector system. For years it was a clinical-stage, cash-burning research company (formerly Intrexon), but in August 2025 it earned full FDA approval for Papzimeos (zopapogene imadenovec, formerly PRGN-2012), the first approved immunotherapy for recurrent respiratory papillomatosis, a rare disease caused by HPV 6 and 11 in which benign tumors recur in the airway and typically require repeated surgeries. Papzimeos is given as four subcutaneous injections over roughly 12 weeks and is designed to trigger an immune response against HPV-infected cells. Precigen also runs Exemplar, a small research-models and services business.
The investment picture is a classic single-product launch: revenue jumped from near zero to about $21.6 million of Papzimeos net product sales in the first quarter of 2026, yet the stock carries a roughly $2 billion market capitalization, so the market is paying for the launch trajectory rather than trailing results. Bulls point to the unmet need, orphan pricing, broad payer coverage, a permanent J-code, and a European filing under review. The counterweight is heavy single-asset concentration, a still-thin cash position relative to burn, and the ordinary risk that a rare-disease launch ramps slower than hoped. Walnut is not an investment adviser and this is descriptive context, not a recommendation.
What's driving Precigen, Inc. (PGEN)?
1. Papzimeos launch ramp
Papzimeos is the entire near-term thesis, and early launch metrics look constructive: roughly 400 hub-enrolled patients, payer coverage for about 297 million US lives, and a permanent J-code effective April 2026 that eases reimbursement. Net product revenue of about $21.6 million in Q1 2026, up from near zero a year earlier, shows the ramp has begun. The pace of new-patient starts over the next few quarters is the metric that matters most.
2. Path to cash-flow break-even
Management has framed 2026 around reaching cash-flow break-even by year-end, funded by existing resources plus expected Papzimeos revenue. Hitting that target would materially reduce the dilution risk that has long shadowed the stock. Missing it would likely force another capital raise at whatever the share price happens to be.
3. Geographic and pipeline expansion
A marketing application for Papzimeos is under review with the EMA, which could open a European revenue stream. Precigen also retains earlier-stage AdenoVerse and cell-therapy programs in oncology and infectious disease, though these are years from commercialization and carry the usual clinical-trial risk. Any pipeline read-outs are optional upside, not the base case.
What are the risks to Precigen, Inc. (PGEN)?
PGEN is a single-product company, so any Papzimeos setback (slower uptake, reimbursement friction, safety signals, or manufacturing issues) would hit the whole thesis at once. The roughly $2 billion market cap sits far ahead of trailing revenue, so the valuation embeds aggressive launch assumptions that leave little margin for disappointment. Cash of about $100 million against ongoing operating losses means a shortfall or slower ramp could require dilutive financing. The RRP niche, while high-need, is small, and competitors such as Inovio's INO-3107 are advancing. As a formerly perennially loss-making biotech, the stock has historically been volatile and heavily shorted.
How is Precigen, Inc. (PGEN) valued? (approximate, MAY 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Precigen, Inc.'s investor relations page or your broker.
- Stock price: ~$5.64 (Jul 2026)
- Market cap: ~$2.0B
- Shares outstanding: ~356.5M
- Revenue (Q1 2026): ~$23.3M total (~$21.6M Papzimeos)
- Net loss (Q1 2026): ~$7.9M (EPS ~-$0.02)
- Cash & investments: ~$100.4M (Dec 2025)
Precigen transitioned to commercial stage with the 2025 FDA approval of Papzimeos, and Q1 2026 revenue of about $23.3 million came almost entirely from that launch versus roughly $1.3 million a year earlier. Because trailing revenue is still small relative to a roughly $2 billion market cap, conventional multiples are not meaningful and the stock trades on forward launch expectations. Management targets cash-flow break-even by the end of 2026, funded by cash on hand plus expected Papzimeos sales.
Who competes with Precigen, Inc. (PGEN)?
RRP-focused therapy developers
The most direct comparison is Inovio Pharmaceuticals, whose INO-3107 is an HPV-targeted DNA immunotherapy in development for the same recurrent respiratory papillomatosis indication. Precigen's Papzimeos is first to market with full FDA approval, but Inovio is the clearest pipeline rival in this specific niche.
Gene- and cell-therapy biotechs
PGEN sits among small- and mid-cap gene- and cell-therapy companies pursuing rare and hard-to-treat diseases, a group that includes names like Krystal Biotech, uniQure, and other single-asset or platform biotechs. These peers share the same launch-execution and financing dynamics rather than competing for the same patients.
Broad immuno-oncology and HPV players
Precigen's earlier pipeline overlaps conceptually with large immuno-oncology and HPV-disease efforts from companies such as Merck (pembrolizumab and combinations). These are far larger and diversified, and are relevant mainly as a reminder that well-capitalized incumbents operate in adjacent HPV-driven disease areas.
How to invest in Precigen, Inc. (PGEN)
There are three common ways to get PGEN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so PGEN sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where PGEN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Precigen, Inc. (PGEN)
PGEN is a launch-stage rare-disease biotech whose value now hinges almost entirely on how fast Papzimeos scales toward the cash-flow break-even the company is targeting.
More on Precigen, Inc. (PGEN)
Whether PGEN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PGEN a buy?, and where the stock could go from here in the PGEN stock forecast.
For income investors, whether PGEN pays a dividend and how the payout looks is covered in does PGEN pay a dividend?
Build a basket around PGEN with Walnut
Use Precigen, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Precigen do?
+
Precigen is a biopharmaceutical company that develops precision gene and cell therapies using platforms like its AdenoVerse gorilla-adenovector system. Its first and only commercial product is Papzimeos, an FDA-approved immunotherapy for recurrent respiratory papillomatosis (RRP).
What is Papzimeos?
+
Papzimeos (zopapogene imadenovec, formerly PRGN-2012) is Precigen's gene-therapy immunotherapy that received full FDA approval in August 2025 for adults with RRP. It is delivered as four subcutaneous injections over about 12 weeks and aims to trigger an immune response against cells infected by HPV 6 and 11.
Is Precigen profitable?
+
No. Precigen reported a net loss of about $7.9 million in the first quarter of 2026, though that was narrower than a year earlier as Papzimeos revenue began to scale. Management has said it targets reaching cash-flow break-even by the end of 2026.
How much revenue does Precigen generate?
+
Total revenue was about $23.3 million in Q1 2026, including roughly $21.6 million from Papzimeos and about $1.7 million from its Exemplar research-models business, up sharply from around $1.3 million a year earlier as the launch ramped.
What is Precigen's market cap?
+
Precigen's market capitalization was around $2.0 billion in mid-2026, with the stock near $5.64 and roughly 356.5 million shares outstanding. That valuation sits well above trailing revenue, reflecting expectations tied to the Papzimeos launch.
What are the biggest risks for PGEN?
+
The main risks are single-product concentration in Papzimeos, a valuation that runs ahead of trailing revenue, a cash balance of about $100 million against ongoing losses that could require dilutive financing, and a small target market. As a formerly perennial loss-maker, the stock has also been historically volatile.
Who competes with Precigen?
+
In its lead RRP indication, the clearest pipeline rival is Inovio Pharmaceuticals with INO-3107. More broadly, PGEN sits among small gene- and cell-therapy biotechs, and its earlier programs touch immuno-oncology and HPV-disease areas where larger players like Merck operate.
Does Precigen pay a dividend?
+
No. Precigen does not pay a dividend. Like most launch-stage biotechs, it reinvests its resources into commercializing Papzimeos and advancing its pipeline rather than returning cash to shareholders.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Precigen, Inc.'s investor relations page or your broker before making investment decisions.